EU/3/16/1800

About

On 12 December 2016, orphan designation (EU/3/16/1800) was granted by the European Commission to Alan Boyd Consultants Ltd, United Kingdom, for dantrolene sodium for the treatment of Wolfram syndrome.

The sponsorship was transferred to Boyd Consultants Limited, Ireland, in March 2019.

Key facts

Active substance
Dantrolene sodium
Disease / condition
Treatment of Wolfram syndrome
Date of first decision
12/12/2016
Outcome
Positive
EU designation number
EU/3/16/1800

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Boyd Consultants Limited
Dublin City University
DCU Invent
Glasnevin
Dublin 9
Ireland
Tel. +44 1270 270010
E-mail: regulatory@boydconsultants.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating